WG5 and IMMUPARKNET CA21117 COST Action invites you to join our second webinar session with Dr. Guillaume Dorothée that will take place online on January 18th 2024, 3:00 pm (CET).
Please register in advance here. After registration, you will receive a confirmation email containing the information on how to access the webinar.
Looking forward to meeting you all there!
Share this post
IMMUPARKNET WG5 article entitled “IMMUnity Unveiled: A Translational NETwork for tackling PARKinson’s Disease – IMMUPARKNET” has just been published on Open Research Europe. The Open Letter...
IMMUPARKNET COST Action recently concluded the first training school entitled “Models for Parkinson’s Disease: From Basics to Translation” held at the Faculty of Health Sciences,...
It is with great pleasure that we anounce that Work Group 1’s IMMUPARKNET paper has been published in Brain, entitled: “The immune system in Parkinson’s...
Short-term Scientific Missions (STSM) are institutional visits aimed at supporting individual mobility and fostering collaborations by allowing scientists to visit an institution and contribute to...
We’re thrilled to share the latest publication from our Working Group 2 (WG2) at IMMUPARKNET COST Action 21117! Entitled “Experimental Models to Study Immune Dysfunction...
🎉 Exciting News from IMMUPARKNET COST Action 21117 Annual Meeting! 🎉 This year’s IMMUPARKNET COST Action Annual Conference took place in the beautiful city of...
COST (European Cooperation in
Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.
The Action focuses on Parkinson’s disease (PD) challenges and aims at establishing an innovative, multi-interdisciplinary Network, fostering the exchange of expertise among outstanding experts, from different countries and institutions, involving scientists studying immunity in PD but also immunity in other neurodegenerative diseases.
MoU – 031/22
CSO Approval date – 27/05/2022
Start date – 20/09/2022
End date – 19/09/2026
Design by Boutik
